Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

SUNSHINE LAKE PHARMA CO., LTD.

廣東東陽光藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6887)

VOLUNTARY ANNOUNCEMENT
SUCCESSFUL INCLUSION OF OLORIGLIFLOZIN CAPSULES IN THE 2026 NATIONAL REIMBURSEMENT DRUG LIST

This announcement is made by Sunshine Lake Pharma Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors (the "**Board**") of the Company is pleased to announce that, Olorigliflozin Capsules (brand name: Dong Ze'an® (東澤安®)) (the "**Product**"), a sodium-glucose cotransporter 2 inhibitor (SGLT-2 inhibitor) and Class 1 innovative drug independently developed by the Group, has recently been successfully included in the latest National Catalogue of Drugs for Basic Medical Insurance, Maternity Insurance and Work-related Injury Insurance (2026) (the "**2026 National Reimbursement Drug List**") published by the National Healthcare Security Administration of China. The 2026 National Reimbursement Drug List will officially take effect on 1 January 2027.

OLORIGLIFLOZIN CAPSULES

The Product was approved for marketing by the National Medical Products Administration of the PRC in January 2026. It is indicated for **improving glycemic control in adult patients with type 2 diabetes mellitus (T2DM)**, either as monotherapy or in combination with metformin. Independently developed by the Group with proprietary intellectual property rights, the Product is an SGLT-2 inhibitor that promotes urinary glucose excretion through potent inhibition of renal SGLT-2, while moderately inhibiting intestinal SGLT-1 to reduce glucose or galactose absorption, effectively mitigating sharp postprandial blood glucose fluctuations and achieving synergistic control of both fasting and postprandial blood glucose through a "whole-course, dual-pathway" approach.

The marketing approval of the Product was supported by two multicenter, randomized, double-blind, controlled Phase III clinical studies. Both Phase III clinical studies demonstrated that 24 weeks of treatment with Olorigliflozin, either as monotherapy or in combination with metformin, significantly reduced glycated hemoglobin (HbA1c), and comprehensively lowered fasting and postprandial blood glucose levels, while also delivering multiple benefits, including improvements in blood pressure and body weight.

The efficacy remained stable through 52 weeks of treatment. The Product also demonstrated notable benefits in improving energy metabolism, in line with the current trend towards comprehensive management of ''blood glucose, body weight and blood pressure'' in diabetes treatment. During the clinical trials, the Product was generally well tolerated, with no significant difference in the incidence of adverse reactions compared with the placebo group.

THE GROUP'S STRATEGY IN THE FIELD OF DIABETES TREATMENT

The Group has long been involved in the treatment of diabetes with a comprehensive product plan and a complete product line in place. The Group has independently researched and developed seven insulin products, namely, Recombinant Human Insulin Injection, Insulin Glargine Injection, Insulin Aspart Injection, Insulin Aspart 30 Injection, Mixed Protamine Human Insulin Injection (30R), Insulin Degludec Injection, and Insulin Degludec and Insulin Aspart Injection, all of which have been approved for marketing.

In terms of the R&D pipeline, the Group's HEC-151, an innovative ultra-long- acting weekly insulin formulation, has entered Phase I clinical trials. Moving forward, this candidate will form a multi-tiered product echelon comprising ''daily formulations — weekly formulations — combination formulations'' alongside currently marketed products, enabling the continuous iterative upgrading of the Group's insulin product pipeline.

In terms of global expansion, the Group's self-developed Insulin Glargine Injection has received an approval letter from the United States Food and Drug Administration at the end of April 2026, making it the fourth insulin glargine product approved for marketing in the United States, and the Company the first PRC pharmaceutical company to commercialize an insulin glargine product in the United States market. Going forward, the Group will continue to advance the overseas registration and approval processes for various insulin products, including Insulin Aspart and Insulin Degludec, so as to steadily expand the global footprint of its insulin product portfolio, increase its international market share, enhance its international operational capabilities and brand influence, and bring PRC-developed insulin products to the global market to benefit people with diabetes worldwide.

By order of the Board
Sunshine Lake Pharma Co., Ltd.
Dr. ZHANG Yingjun
Chairman

Dongguan, the PRC
15 November 2026

As at the date of this announcement, the executive Directors are Dr. ZHANG Yingjun, Mr. JIANG Juncai and Mr. ZHANG Zhiyong (employee Director), the non-executive Directors are Mr. ZHANG Yushuai, Mr. TANG Xinfa, Mr. ZHU Yingwei and Dr. LI Wenjia, and the independent non-executive Directors are Dr. LI Xintian, Dr. MA Dawei, Dr. LIN Aimei and Dr. YE Tao.